Patient demographics after match
| Overall N=11 022 | Non-FCD N=8253 (74.9%) | FCD N=2769 (25.1%) | P value | |
| Age, mean (SD) | 46.9 (16.4) | 46.9 (16.4) | 46.9 (16.6) | 0.876 |
| Female sex | 5598 (50.8) | 4200 (50.9) | 1398 (50.5) | 0.714 |
| Malnutrition | 502 (4.6) | 363 (4.4) | 139 (5.0) | 0.175 |
| Payer type | 0.694 | |||
| Commercial | 9684 (87.9) | 7257 (87.9) | 2427 (87.7) | |
| Medicare | 1338 (12.1) | 996 (12.1) | 342 (12.3) | |
| Anti-TNF therapy* | 4021 (36.5) | 3011 (36.5) | 1010 (36.5) | 0.993 |
| CCI | 0.994 | |||
| 0 | 5551 (50.4) | 4154 (50.3) | 1397 (50.5) | |
| 1 | 2238 (20.3) | 1677 (20.3) | 561 (20.3) | |
| 2+ | 3233 (29.3) | 2422 (29.4) | 811 (29.3) |
All data are n (%) unless otherwise stated.
*Anti-TNF therapy included adalimumab, certolizumab pegol, ustekinumab, vedolizumab, and infliximab.
CCI, Charlson Comorbidity Index; FCD, fibrostenotic Crohn’s disease; TNF, tumour necrosis factor.